ALXO is the ticker symbol for ALX ONCOLOGY HOLDINGS INC, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks ALXO with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is ALXO a good stock to buy?

ALXO is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/ALXO.

Where does 13F Pro source ALXO data?

All ALX ONCOLOGY HOLDINGS INC fundamentals and ownership data come directly from SEC EDGAR. ALX ONCOLOGY HOLDINGS INC files with the SEC under CIK 1810182. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

ALX ONCOLOGY HOLDINGS INC(ALXO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

ALX ONCOLOGY HOLDINGS INC (ALXO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ALXO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), ALX ONCOLOGY HOLDINGS INC reports net income of $-18.0M, free cash flow of $-16.1M. Top institutional holders of ALXO by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., venBio Partners, BlackRock, based on the most recent SEC filings. ALXO trades on the Nasdaq exchange and files with the SEC under CIK 1810182. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALXO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALX ONCOLOGY HOLDINGS INC directly from SEC EDGAR.

Net Income

$-18.0M

Free Cash Flow

$-16.1M

ALXO key financials by period

ALX ONCOLOGY HOLDINGS INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2020	10-K	$1.2M	$-45.7M	—
FY 2019	10-K	$4.8M	$-19.2M	—
FY 2018	10-K	$2.1M	$-13.7M	—

Institutions holding ALXO

Institutional investors reporting a position in ALX ONCOLOGY HOLDINGS INC on SEC Form 13F.
Institution	Shares	Value	Reported
RA CAPITAL MANAGEMENT, L.P.	13,011,849	$26.9M	2026-06-30
venBio Partners	12,884,638	$26.7M	2026-06-30
BlackRock	7,399,530	$15.3M	2026-06-30
Redmile Group	7,392,504	$15.3M	2026-06-30
Blackstone	6,593,543	$13.6M	2026-06-30
DRIEHAUS CAPITAL MANAGEMENT	6,025,240	$12.5M	2026-06-30
SILVERARC CAPITAL MANAGEMENT	5,744,757	$11.9M	2026-06-30
TCG Crossover Management	5,655,487	$11.7M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	4,973,436	$10.3M	2026-06-30
Vivo Capital	3,184,713	$6.6M	2026-06-30

SEC EDGAR: CIK 1810182 →

ALX ONCOLOGY HOLDINGS INC

ALXO

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.